AFP and liver cancer: Furthermore, even though much progress has been achieved, a current screening methodology, such as computed tomography, and a biomarker, such as alpha-fetoprotein (AFP), exhibit low sensitivity and specificity for detecting early liver cancers that can hardly be acceptable in a clinical field [28,29].